Development and characterization of an equine infectious anemia virus env-pseudotyped reporter virus

Clinical and Vaccine Immunology

Volumn 15, Issue 7, 2008, Pages 1138-1140

  Tallmadge, R L ^a   Brindley, M A ^b   Salmans, J ^a   Mealey, R H ^a   Maury, W ^b   Carpenter, S ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ARTICLE; EQUINE INFECTIOUS ANEMIA VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PSEUDOTYPING; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS TYPING;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CELL LINE; EQUINE INFECTIOUS ANEMIA; GENETIC ENGINEERING; HORSES; INFECTIOUS ANEMIA VIRUS, EQUINE; NEUTRALIZATION TESTS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 47649088478     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00088-08     Document Type: Article

References (22)

1. Belshan, M., P. Baccam, J. L. Oaks, B. A. Sponseller, S. C. Murphy, J. Cornette, and S. Carpenter. 2001. Genetic and biological variation in equine infectious anemia virus Rev correlates with variable stages of clinical disease in an experimentally infected pony. Virology 279:185-200.
2. Cham, F., P. F. Zhang, L. Heyndrickx, P. Bouma, P. Zhong, H. Katinger, J. Robinson, G. van der Groen, and G. V. Quinnan, Jr. 2006. Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity. Virology 347:36-51.
3. Cronin, J., X. Y. Zhang, and J. Reiser. 2005. Altering the tropism of lentiviral vectors through pseudotyping. Curr. Gene Ther. 5:387-398.
4. Cunningham, T. P., R. C. Montelaro, and K. E. Rushlow. 1993. Lentivirus envelope sequences and proviral genomes are stabilized in Escherichia coli when cloned in low-copy-number plasmid vectors. Gene 124:93-98.
5. Hammond, S. A., S. J. Cook, D. L. Lichtenstein, C. J. Issel, and R. C. Montelaro. 1997. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J. Virol. 71:3840-3852.
6. Hammond, S. A., F. Li, B. M. McKeon, Sr., S. J. Cook, C. J. Issel, and R. C. Montelaro. 2000. Immune responses and viral replication in long-term in-apparent carrier ponies inoculated with equine infectious anemia virus. J. Virol. 74:5968-5981.
7. Johnson, L. G., J. P. Mewshaw, H. Ni, T. Friedmann, R. C. Boucher, and J. C. Olsen. 1998. Effect of host modification and age on airway epithelial gene transfer mediated by a murine leukemia virus-derived vector. J. Virol. 72:8861-8872.
8. Kolokoltsov, A. A., E. Wang, T. M. Colpitts, S. C. Weaver, and R. A. Davey. 2006. Pseudotyped viruses permit rapid detection of neutralizing antibodies in human and equine serum against Venezuelan equine encephalitis virus. Am. J. Trop. Med. Hyg. 75:702-709.
9. Li, M., F. Gao, J. R. Mascola, L. Stamatatos, V. R. Polonis, M. Koutsoukos, G. Voss, P. Goepfert, P. Gilbert, K. M. Greene, M. Bilska, D. L. Kothe, J. F. Salazar-Gonzalez, X. Wei, J. M. Decker, B. H. Hahn, and D. C. Montefiori. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79:10108-10125.
10. + cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/PR proteins. J. Virol. 68:1459-1467.
11. Meunier, J.-C., R. S. Russell, V. Goossens, S. Priem, H. Walter, E. Depla, A. Union, K. N. Faulk, J. Bukh, S. U. Emerson, and R. H. Purcell. 2008. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the E1 glycoprotein of hepatitis C virus. J. Virol. 82:966-973.
12. Nie, Y., G. Wang, X. Shi, H. Zhang, Y. Qiu, Z. He, W. Wang, G. Lian, X. Yin, L. Du, L. Ren, J. Wang, X. He, T. Li, H. Deng, and M. Ding. 2004. Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. J. Infect. Dis. 190:1119-1126.
13. Oaks, J. L., T. C. McGuire, C. Ulibarri, and T. B. Crawford. 1998. Equine infectious anemia virus is found in tissue macrophages during subclinical infection. J. Virol. 72:7263-7269.
14. Olsen, J. C. 1998. Gene transfer vectors derived from equine infectious anemia virus. Gene Ther. 5:1481-1487.
15. Perryman, L. E., K. I. O'Rourke, and T. C. McGuire. 1988. Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection. J. Virol. 62:3073-3076.
16. Sellon, D. C., F. J. Fuller, and T. C. McGuire. 1994. The immunopathogenesis of equine infectious anemia virus. Virus Res. 32:111-138.
17. Sellon, D. C., S. T. Perry, L. Coggins, and F. J. Fuller. 1992. Wild-type equine infectious anemia virus replicates in vivo predominantly in tissue macrophages, not in peripheral blood monocytes. J. Virol. 66:5906-5913.
18. Smith, T. A., E. Davis, and S. Carpenter. 1998. Endotoxin treatment of EIAV-infected horse macrophage cultures decreases production of infectious virus. J. Gen. Virol. 79:747-755.
19. Sponseller, B. A., W. O. Sparks, Y. Wannemuehler, Y. Li, A. K. Antons, J. L. Oaks, and S. Carpenter. 2007. Immune selection of equine infectious anemia virus env variants during the long-term inapparent stage of disease. Virology 363:156-165.
20. Zhang, W., S. M. Lonning, and T. C. McGuire. 1998. Gag protein epitopes recognized by ELA-A-restricted cytotoxic T lymphocytes from horses with long-term equine infectious anemia virus infection. J. Virol. 72:9612-9620.
21. Zolla-Pazner, S., P. Zhong, K. Revesz, B. Volsky, C. Williams, P. Nyambi, and M. K. Gorny. 2004. The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1. AIDS Res. Hum. Retrovir. 20:1254-1258.
22. Zwick, M. B., R. Jensen, S. Church, M. Wang, G. Stiegler, R. Kunert, H. Katinger, and D. R. Burton. 2005. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol. 79:1252-1261.